2026 US Cannabis Reform: Schedule III Rescheduling Explained

Introduction

United States cannabis policy shifted in a way few operators expected. On 22 April 2026 the federal government moved a defined class of marijuana from Schedule I to Schedule III of the Controlled Substances Act. This was not a ballot measure and not full legalization. It was a targeted regulatory change that reshapes tax, research, and quality expectations for part of the cannabis market while leaving the rest untouched.

For cannabis businesses, and for the Canadian licensed producers who supply international markets, this is a compliance story more than a political one. Rescheduling brings cannabis closer to the pharmaceutical framework, which means quality systems, documentation, and validation start to matter in ways they did not before. This guide explains what changed, what is still under review, and how companies can prepare. For related reading on export readiness, see our guide to GMP certification for cannabis.

Executive Summary

Effective 22 April 2026, the United States Department of Justice and the Drug Enforcement Administration placed two categories of marijuana into Schedule III: products approved by the Food and Drug Administration that contain marijuana, and marijuana handled under a qualifying state medical marijuana licence. Everything else, including adult-use recreational cannabis, bulk marijuana, and synthetic THC, remains in Schedule I. An expedited administrative hearing running from 29 June to 15 July 2026 is considering whether the broader rescheduling of marijuana should follow. The most immediate business effect is tax related, because Section 280E of the tax code no longer blocks ordinary business deductions for operators that are no longer trafficking a Schedule I or II substance. Banking reform through the SAFER Banking Act has been reintroduced in Congress but is not yet law. The direction of travel points toward tighter, more pharmaceutical-style oversight, so quality and documentation readiness is now a competitive advantage.

What Changed in 2026: Marijuana Rescheduled to Schedule III

What it is: On 22 April 2026 the federal government created a two-tier system. A narrow class of marijuana moved to Schedule III, while the rest of the market stayed in Schedule I. Why it matters: Schedule III is where many prescription medicines sit, so the move begins to align part of the cannabis market with pharmaceutical controls. What to do: Confirm which schedule your products fall under, because your tax, research, and compliance obligations now depend on that answer.

The change followed a Presidential Executive Order on increasing medical marijuana and cannabidiol research, and it was implemented through a Department of Justice final order and a Federal Register rule. The Drug Enforcement Administration published the action on its marijuana rescheduling regulatory actions page. Importantly, rescheduling did not remove marijuana from federal control. It reclassified a defined portion of it. The table below shows how the two tiers break down.

Category	Federal schedule (as of 22 April 2026)
FDA-approved products containing marijuana	Schedule III
Marijuana under a qualifying state medical marijuana licence	Schedule III
Adult-use recreational marijuana (state-legal or not)	Schedule I
Bulk marijuana not yet in an approved product	Schedule I
Synthetic THC	Schedule I

The distinction is deliberate. The federal action rewarded products that already sit inside a recognized quality or licensing framework, whether that is FDA approval or a qualifying state medical programme. Recreational cannabis, which operates outside those frameworks at the federal level, was left where it was.

Why the Rescheduling Matters for Cannabis Businesses

What it is: Moving to Schedule III unlocks tax relief, eases research, and starts to open the door to more normal banking and business operations for the affected products. Why it matters: These are the practical barriers that have squeezed cannabis margins for years. What to do: Assess where your business would benefit, and where new pharmaceutical-style expectations may apply.

For years, the biggest complaints from cannabis operators were not about legality in their own state. They were about the federal penalties that came with Schedule I status: punishing tax treatment, limited access to banking, and heavy restrictions on research. Rescheduling addresses the first of these directly and sets up movement on the others. The three areas to watch are tax, research, and banking.

The Research Angle

The rescheduling grew out of an executive order focused on expanding medical marijuana and cannabidiol research, so it is no surprise that research is one of the clearest beneficiaries. Schedule I status has long made cannabis research slow and difficult, because working with the substance required registrations and controls designed for drugs with no accepted medical use. Moving FDA-approved and state-licensed medical marijuana to Schedule III lowers some of those barriers and makes it easier for researchers and manufacturers to generate the safety and efficacy data that regulators expect. For companies, more research also means more scrutiny of data integrity and study documentation, which reinforces the shift toward pharmaceutical-style quality expectations.

Section 280E Tax Relief Explained

What it is: Section 280E of the Internal Revenue Code bars businesses that traffic Schedule I or II drugs from deducting ordinary business expenses. Why it matters: It has pushed some cannabis operators to effective federal tax rates approaching or exceeding 75 percent. What to do: If your products moved to Schedule III, work with a qualified tax adviser on how the relief applies to your business.

Because Section 280E only applies to Schedule I and II substances, operators whose products moved to Schedule III are, in general, no longer caught by it. In practice this means a state-licensed medical marijuana manufacturer, distributor, or dispensary can now deduct ordinary and necessary business expenses in addition to cost of goods sold. The United States Department of the Treasury and the Internal Revenue Service have announced that formal tax guidance will follow, as noted in the Treasury press release on the process for tax guidance.

For calendar-year taxpayers, the transition rule is expected to treat the relief as applying from 1 January 2026, which avoids splitting a single tax year into pre-rescheduling and post-rescheduling periods. The exact mechanics will depend on the final Treasury and IRS guidance.

The DEA Hearing and What Comes Next

What it is: An expedited administrative hearing is examining whether the broader rescheduling of all marijuana to Schedule III should proceed. Why it matters: The outcome could extend Schedule III benefits far beyond the current medical and FDA-approved products. What to do: Follow the process, but plan around what is already law rather than what might happen.

The same order that rescheduled medical and FDA-approved marijuana also launched an expedited hearing before an administrative law judge. It began on 29 June 2026 and is scheduled to conclude no later than 15 July 2026, with a recess on 3 July and a return on 6 July. The purpose is to receive factual evidence and expert opinion on whether marijuana as a whole should move to Schedule III. The Federal Register notices for the action are published in the Federal Register rescheduling documents.

Legal challenges are widely expected, and the final scope of rescheduling is not settled. Businesses should be careful not to build strategy on an assumption that full Schedule III status is coming for every product. The prudent approach is to prepare quality and documentation systems now, so that whichever way the hearing lands, the business is ready to operate under closer federal scrutiny.

Banking Reform: Where the SAFER Banking Act Stands

What it is: The SAFER Banking Act would give financial institutions clearer protection to serve state-legal cannabis businesses. Why it matters: Many operators still run largely in cash, which raises safety and compliance risk. What to do: Improve financial recordkeeping now, so you are ready to move into mainstream banking if the law changes.

Banking reform is moving separately through Congress. The SAFER Banking Act was reintroduced on 25 June 2026 in the 119th Congress with bipartisan sponsors. Earlier versions of the bill passed the House of Representatives several times between 2019 and 2022, and the Senate Banking Committee approved the SAFER version in 2023, but it has never passed a full Senate vote. As of mid-2026 it remains a bill, not a law. Coverage of the reintroduction is available from industry reporting on the SAFER Banking Act. Until it passes, banking access remains limited and inconsistent.

What This Means for Canadian Licensed Producers and Exporters

What it is: US rescheduling changes the competitive landscape for the global medical cannabis trade that Canadian producers help supply. Why it matters: Canadian licensed producers already operate under quality frameworks that the US market is beginning to move toward. What to do: Use your existing quality maturity as a strategic advantage and keep export documentation strong.

Canadian licensed producers are among the most experienced quality-driven cannabis suppliers in the world. In the first quarter of 2026, Germany imported more than 50,000 kilograms of medical cannabis flower, and Canadian producers supplied roughly 53 percent of it, much of it under EU-GMP certification. As the United States nudges medical marijuana toward pharmaceutical-style controls, the discipline that Canadian producers have already built for Health Canada and European markets becomes even more valuable. For a refresher on the standards involved, see our comparison of GMP and Good Production Practices for cannabis.

Canadian producers exploring the United States should not assume that Schedule III opens an easy import route. Federal controls remain, and any cross-border activity involving controlled substances requires careful legal and regulatory planning. Our regulatory affairs, licensing, and import and export team helps producers map pathways before committing resources.

What US Cannabis Operators Should Do Now

What it is: A practical set of readiness actions that make sense regardless of how the hearing and banking bills resolve. Why it matters: Federal oversight is tightening, and quality systems take months to build. What to do: Start with a gap assessment and prioritize documentation, validation, and audit readiness.

Whether or not your products moved to Schedule III, the direction is clear: the federal government is drawing cannabis closer to the pharmaceutical model. Companies that already run mature quality systems will adapt faster and face fewer surprises. The table below sets out priority actions.

Priority action	Why it matters
Run a quality and compliance gap assessment	Identifies where current systems fall short of pharmaceutical-style expectations
Strengthen SOPs and documentation	Records that are complete and contemporaneous are the backbone of any regulated operation
Build or validate quality control testing	Schedule III products face closer scrutiny of identity, potency, and contaminant testing
Prepare for audits and inspections	Mock inspections reveal gaps before regulators or partners do
Improve financial recordkeeping	Positions the business for 280E relief and future banking access
Plan validation and qualification	Equipment and process validation are central to pharmaceutical-grade production

A structured gap assessment is the fastest way to turn this list into a plan. Our audit and inspection readiness services and quality assurance services are built for exactly this kind of maturity step.

US Cannabis Reform Compliance Checklist

Use this checklist as a starting point to gauge your readiness for a more pharmaceutical-style federal environment.

Confirm which federal schedule each of your products falls under
Review your tax position with a licensed professional regarding Section 280E
Document a complete, version-controlled set of standard operating procedures
Ensure batch records and test results are contemporaneous and retrievable
Validate quality control testing for identity, potency, and contaminants
Complete a gap assessment against pharmaceutical-style quality expectations
Run at least one mock inspection and close every finding
Strengthen financial recordkeeping in anticipation of banking reform
Keep import and export documentation aligned with current controlled-substance rules
Monitor the DEA hearing outcome and any legal challenges without over-committing to an assumed result

Common Mistakes to Avoid

Treating rescheduling as full legalization. It is a two-tier change. Adult-use cannabis remains in Schedule I, and federal controls still apply.

Assuming automatic 280E relief. Relief follows the products that actually moved to Schedule III, and mixed operations may need to apportion expenses.

Waiting for the hearing before acting. Quality systems take months to build. Preparing now is cheaper than reacting later.

Ignoring documentation quality. As oversight moves toward the pharmaceutical model, incomplete or inconsistent records become a serious liability.

Confusing a bill with a law. The SAFER Banking Act has been reintroduced but is not yet law, so plan around current reality.

Overlooking testing and validation. Schedule III products face closer scrutiny of testing and process validation than most recreational operations are used to.

Frequently Asked Questions

Did the United States legalize marijuana in 2026?

No. The 2026 action rescheduled a defined class of marijuana, specifically FDA-approved products and marijuana under a qualifying state medical licence, from Schedule I to Schedule III. It did not legalize marijuana, and adult-use recreational cannabis remains in Schedule I under federal law.

What is the difference between Schedule I and Schedule III?

Schedule I is reserved for substances the federal government treats as having no accepted medical use and a high potential for abuse. Schedule III substances are recognized as having accepted medical uses with a lower potential for abuse, and many prescription medicines sit there. Moving to Schedule III eases tax and research restrictions.

How does rescheduling affect Section 280E taxes?

Section 280E blocks ordinary business deductions for companies trafficking Schedule I or II drugs. Products that moved to Schedule III are generally no longer caught by it, so affected operators can deduct ordinary business expenses beyond cost of goods sold. Treasury and the IRS are issuing guidance, and businesses should confirm their position with a tax professional.

Is cannabis banking now allowed?

Not automatically. Banking reform is moving through the SAFER Banking Act, which was reintroduced in Congress in June 2026 but has not become law. Until it passes, access to banking for cannabis businesses remains limited and inconsistent.

What does the DEA hearing decide?

The expedited hearing that runs from 29 June to 15 July 2026 examines whether marijuana as a whole should move to Schedule III. It gathers factual evidence and expert opinion for the administrative process. The outcome is not final, and legal challenges are expected.

How should Canadian producers respond to US reform?

Canadian licensed producers already operate under mature quality frameworks that the United States is beginning to move toward. The practical response is to keep quality systems and export documentation strong, and to seek regulatory advice before pursuing any cross-border activity involving controlled substances.

How MFLRC Can Help

MF License and Regulatory Consultants helps cannabis businesses prepare for a more pharmaceutical-style regulatory environment on both sides of the border. We run gap assessments and mock inspections, build the SOPs and quality systems that closer oversight demands, and provide QAP support, validation planning, and licensing guidance across cannabis and hemp operations. For producers weighing cross-border strategy, our licensing and import and export support maps the regulatory pathway before you commit resources. With more than 20 years of quality and regulatory experience across cannabis, pharmaceuticals, and natural health products, our senior-led team turns regulatory change into a clear plan.

Preparing for a tighter federal framework, or planning international expansion? Contact MFLRC for practical, senior-led guidance tailored to your business and your markets.

Book a Consultation

Conclusion

The 2026 rescheduling is one of the most significant federal cannabis developments in decades, but it is narrower than the headlines suggest. Medical and FDA-approved marijuana moved to Schedule III, unlocking real tax relief and easier research, while adult-use cannabis stayed in Schedule I. A hearing is testing whether the rest should follow, banking reform is back on the table, and legal challenges are likely. Through all of that uncertainty, one thing is steady: the federal system is pulling cannabis closer to the pharmaceutical model, and quality, documentation, and validation are becoming the price of admission. Businesses that build those systems now will be ready whatever the process decides.